Cefoperazone in lower respiratory tract infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Internal Medicine

Background:

• Lower respiratory tract infections (LRTIs) are common causes of hospitalization.
• Bacterial pathogens like Haemophilus influenzae and Streptococcus pneumoniae frequently cause LRTIs.
• Intravenous antibiotics are crucial for managing severe bacterial LRTIs.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous bolus cefoperazone in treating hospitalized patients with LRTIs.
• To assess the clinical outcomes and side effect profile of cefoperazone therapy.

Main Methods:

• Seventeen hospitalized patients with various LRTIs received intravenous cefoperazone (1.0g every 12 hours) for at least six days.
• Cultures identified causative pathogens including Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and mixed anaerobes.
• Isolate sensitivity to cefoperazone was tested.

Main Results:

• All bacterial isolates tested were sensitive to cefoperazone.
• Eleven patients achieved a cure, while four showed improvement.
• Two patients experienced treatment failure, including one with an anaerobic empyema.
• Adverse events and toxicity associated with cefoperazone were infrequent.

Conclusions:

• Cefoperazone demonstrated effectiveness as a therapeutic agent for common lower respiratory tract infections in hospitalized patients.
• The antibiotic was generally well-tolerated, with infrequent side effects.
• Cefoperazone represents a viable treatment option for bacterial LRTIs, pending further investigation.